I'm Dave Windley with Jefferies Healthcare Equity Research. Appreciate your interest in Jefferies London Healthcare Conference. Our next presenting company is Charles River Labs and the company's CEO, Birgit Girshick, who's taken over just this year. So welcome. We've had you at, I think, at least New York. I can't remember if here, but.
Yes.
We certainly have had you in conference settings before, and so appreciate you being here. As I said, Birgit has just recently taken over the CEO seat and has rolled out an impressive strategy. I wanted to give you the opportunity to just talk about the changes that you're instituting under your leadership.
Certainly. So thanks, Dave, for having us. It's always a pleasure to be here. It's actually my second time here in London, and it's a great conference for us to be here. Yes, I've taken over as CEO roughly six months ago, but I've been with Charles River nearly four decades. So what I bring to the CEO role is a lot of knowledge about Charles River, what differentiates us, what our strengths are, but also what our weaknesses are. Based on that, I was basically able to hit the ground running as soon as I was appointed to the role. What I did was roll out a strategic framework called Pathway to Purpose.
We did this to give clarity to our employees and align them around what needs to be done, but also to provide clarity to our board, to our clients, and clarity to our investors, current and potential investors. What Pathway to Purpose is about is the three areas that we need to focus on to continue to be competitive today, but also to be competitive in the future, three years from now, five years from now, or decades from now. What Pathway to Purpose really covers is modernization of our company, and that's something that I have a real urgency about and leaning into a lot. So modernization of our company means that we want to have more scalable, more automated, more digital processes so we can actually be faster and more agile for our clients.
This initiative, called Create the Future, is going to translate and support into $300 million of cost savings between now and the next three years. That is in addition to $300 million of cost savings that we have taken out of the company in the last three years under my leadership. This will translate into approximately 75 basis points of margin improvement in the next few years. We have already made great progress on it. This is an initiative that it's not going to be something that we're going to do, but actually executing on. Just recently, we announced that we implemented an automated production line in our Microbial Solutions facility, increasing capacity by 14%. We talked about Apollo Orchestrate.
Apollo is our client-facing platform that will allow us to digitize our laboratory processes from sample submission through the laboratory all the way into reporting for our Biologics Testing business. The digitization efforts will cover everything from how we structure, organize our data, but also the use of AI. Another important area is our portfolio, and we have made great progress on that. What we want to do is refine our portfolio to make sure that we operate and provide our clients with the highest value services that they really rely on us and really want to buy from us. Earlier this year, we have made two divestitures. Our early discovery assets in Europe was one of them, and our CDMO business that we divested together with our cell supply business. These were two businesses that were great businesses.
However, we are not necessarily the best parent at this stage in the process. In addition, we have made two acquisitions which really strengthen our company. One was a non-human primate facility that allows us to integrate into our supply chain and give our clients the confidence that they actually can run their critical safety assessment studies when they need them. The non-human primate is non-arguably the most critical research model, and this backward integration is incredibly important for us and the industry. We also, at the same time, invested in a NAMs technology. We acquired a company called PathoQuest. This technology will replace in vivo testing in our Biologics Testing business. In addition, it allows us to offer now cell bank characterization, which many of the manufacturers are required to have, from a 20-week normal process down 40%. A real improvement in timelines.
Last but not least, we're focused on client centricity, which the first and the second pillar, modernization and portfolio refinement, actually help us a lot with that. It's also the way we go to market, the way we deal with our clients, the ease of working that our clients experience with a CRO with us. We believe that we are making great progress there. We just signed a strategic partnership, being the primary strategic partner of a top 10 pharmaceutical company. We have worked with this company for a long time and have proven that we are the best partner, and now we were selected the primary partner, which is now literally every biopharmaceutical company selecting Charles River as their top partner. I'm leaning into those areas, and I'm believing that this will provide us with a lot of long-term shareholder value.
Birgit, on that last point that you made, the completing the sweep, essentially, is 10 of the top 10, or did you even say yesterday 20 of the top 20?
Well, don't want to give exact numbers, but the top biopharmaceutical companies see us as their utmost critical partner.
Got it. Okay. DSA is your largest business, that's now reached the mid-single-digit organic growth level. You've had four consecutive quarters of book-to-bill above one. Talked about proposals are still kind of accelerating. I just want to kind of test what you're seeing in the market. Is there any client fragility that still remains? How durable does this recovery feel to you and to your sales team?
Yeah, great question, and really important. Something that we are always concerned about and keep certainly looking at our metrics as well as the macroeconomics. So at this stage, we have a very broad-based stabilization and improvement of all metrics that we are looking at. So, revenue growth came from both biotech as well as global biopharma. Net book-to-bill increase came from both client segments. Proposal rates are up, high single, high double digits year-over-year for five consecutive months now. So everything we're looking at shows us that the demand is back, that our clients are back to work, and that the biotech funding is translating into demand, and global biopharma has, for the most part, completed their restructuring and reprioritization. To your question, what is still outstanding? Where do we still would like to see some improvements? There's actually two areas.
One of the areas is the very early stage funding or early stage company formation. That is generally something that we talk about in relation to our CRADL business, but even with DSA demand, in order to have very long-term sustainable demand, we definitely want to see that bounce back a little bit more. The other area that we still not quite happy with is the availability of pricing. This last quarter in our earnings release, we actually talked about that we have walked back discounting a little bit, or in other words, we are implementing slight pricing increases in our proposals. We were able to win some of that work. Our capture rates have stayed up. I have confidence that we're gaining back some of that pricing power.
Even as we do, and assuming this will hold, we have a bit of a longer way to go with that, because as pricing returns in the bookings, we have to anniversary out our backlog first, because that was booked at the lower rates. Sure pricing will come, but it will be a few quarters before we see it in the revenue.
I appreciate both of those. Just to hover on the pricing for a second, you made the point to me in conversation recently that this point that you just made about some of the older backlog priced less well as what you're seeing now. Can you give us a little bit of chronology there? Where was perhaps pricing bottoming out before it started to improve? Where would that have occurred?
Yeah. If we think about as biotech funding slowed, we worked through some of our backlog. About two years ago, three years ago, as less demand occurred, we had to react to some of the pricing pressures in the industry, so competitive pressures, with some discounts that we had given to clients that we wanted to make sure we can hold, or new clients that we wanted to absolutely win. It was a strategic discounting, never a major discount throughout the whole portfolio, but that kind of stabilized there, so we had to do that for the last couple years.
Now that we're seeing more demand return, we will walk that back, and then we actually can look at more broad-based pricing increase and inflationary increases, as we want to be paid for our work and paid for inflation, because it's really hard, as you know, to maintain your margins with a declining top line and no price, which we actually have done a really good job at.
Got it. Would it be right to say that, like, 2024 and 2025 would have been that couple of years of kind of stable but lower discounted pricing, and then 2026 has seen that start to.
Yeah.
Climb through the discount?
Yes. That's a good way of framing it, but I would say that we're just starting to see that pricing climb.
Okay. Moving on then, within DSA, you have talked about in your long-range plan, a 5%-7% growth framework. I believe that, relevant to our topic here, is about one-third price, two-thirds volume. You have also said you have excluded what we called yesterday moonshots, kind of big AI, big inflation characteristics, future M&A, things like that. What factors would have to happen to make that 5%-7% prove too conservative? Or conversely, what scenarios would make it too optimistic?
Yeah. You summarized that well. At our Investor Day, we actually, Glenn called it moonshots. I cannot say it any better. What we did was our target is looking at what we have visibility in right now, and looking to see what the macroeconomics are, making sure that we are not getting out ahead of ourselves with expectations on funding, but also listening to our clients, particularly the larger clients who have a lot of visibility into the one-year, two-year, three-year pipelines and what we are expecting from there. We took this together with our current metrics, which obviously are only time-based. There is not a huge amount of visibility to come up with a target range that we believe we can meet, so a realistic target range. On purpose, we did not include the moonshots because we have no visibility into those.
Could we see some more pricing? Potentially. Could we see some more demand that is created because AI makes drug development really exciting? Absolutely. But currently, we do not have that visibility, nor do we see these as humongous drivers of our demand. We want to just be really realistic and make sure that what we are laying out there, what we are planning for is doable. What could happen to, obviously, the AI and the pricing could be upsides. What could happen to be at the lower end of that target or even below? What we are really watching for is biotech funding. That is always the big question. Is it stable? Is it improving? Q3 was a little bit lower, but Q4 seems to have stabilized again. We are not seeing anything that would get us off our targets, but that is something that we will continue to watch.
Most importantly, our investments will be done with discipline. As you know, over the last few years, even with declining revenues, because of the discipline that we have in reducing cost, we were able to maintain our margins, and that is going to be something that we will be very disciplined about going forward as well.
Excellent. Thank you for that. Your comment on investments is a great segue to my next question, which is around capacity. Your DSA demand is now improving. Clearly, you want to have the capacity to serve that demand if, for example, some of these moonshots begin to become more material. Your physical in vivo capacity seems to me to be sufficient for a couple of years. What do you think your constraints are or could be? People, study mix, ability to, that is kind of study mix scheduling. Is it model availability? What are the constraints or bottlenecks to your ability to service customer demand that you are focused on?
Yeah, great question. All of those need to come together. That is what it is about, to provide best service, best timelines to our clients. I will take them one by one really quickly, because each of them could be a bottleneck, but each of them are more or less in our control. So you are right. From an in vivo perspective, we have animal rooms. We were slightly ahead, as we should be, in our capacity. When the downturn happened, we had less volume over the last couple of years, so we have a little room to grow into. From a laboratory perspective, we actually continued to grow over the last few years. That is why it makes bioanalysis such a nice area, strategic area for us, which I am sure you will ask me about.
We currently have five organic expansions in that area, some of them coming through now, some next year. So we are actually in really good shape in both areas there. People is not always. We just need to make sure that we are ahead, slightly ahead of the curve, because those people need to be trained. But attrition rates are low, hiring is relatively easy, and our company and our industry are of a lot of interest to newcomers, and we found that hiring people and bringing them on, training them, is relatively easy, not as hard as in the COVID time. The model availability, obviously, with the small animal models, we have our RMS business for that, so we couldn't be in a better position.
From an NHP perspective, which is always the big question for primates, we acquired now two farms, and that allows us to have 80% of our long-range financial target volumes covered with primates for about 80%. So we still will go into the open market a little bit for some, and that is on purpose. That gives us the highest diversity. But we believe that we are as good positioned as possible to leverage all our inputs for winning work and being there for our clients.
Let's jump off of your NHP comment and go to that strategy. You now own about 80% of your supply, as you described. That gives you multiple advantages. I think the market is largely focused on cost, but availability, quality, reliability, timing of study start, all those things that you can turn to your client and show. How do you intend to primarily harvest this advantage? Should we think margin, market share, cementing strategic relationships? How do you monetize the advantage that owning that supply chain now gives you?
Yeah, good question, and certainly something that we're looking, basically with every proposal, every contract that we are writing at what best to do. We absolutely want to be paid for the investment we made. So, we have provided you with margin improvement from this deal, from the latest deal, the Cambodian deal, as well as our Mauritius farm expansion. And we will be disciplined and dedicated in delivering that. So, that's number one. What I'm seeing right now with clients is availability is so high on their list that I think that is really the major point in the industry right now, is that clients want to make sure that they have the animals. So, there is a competitive advantage, and that is there without giving any price concessions. We will continue to work, and the answer really to your question is everything a little bit, right?
We will continue to work with our clients to leverage this competitive advantage, this supply chain, gaining their trust, being the most reliable partner, being the partner that can start their studies when we promise and have the highest quality and best supply of those critical research animals in the industry, and that's what we generated.
To drill in on this a little bit more, as utilization rises, so you have availability, clients want to lock in that availability. You don't have an unending supply of NHPs. It is a scarce resource, and yet with the pipeline moving to biologics, that's what the market needs. As you get toward kind of full utilization, how does this balance between margin and market share, how are you going to titrate that decision?
Yeah. We certainly will look at what's available, what's the growth rate, but we also have long-term contracts. Just to remind you, we price out the study. We want to stay competitive in our study pricing. That includes the animal. It will be, as I said, a little bit of both, but don't expect any of that hyperinflation of price that some expect. We are not modeling that in, and we would ask you not to model that in. We're looking at a reliable trust relationship with our partners and with our customers. There could be a little bit of price, but not the hyperinflation.
All right. We've beaten that horse. That's good. Let's move to bioanalysis. You mentioned your organic investments. Last year about this time, we got to see your Edinburgh facility. You were making some investments there. You have this bio way strategy to kind of carry the client from preclinical to clinical. Expand on how investing in this scale gives you the opportunity to win more business in bioanalysis.
Yeah, certainly. Let me take a quick step back. We did announce an acquisition, and even so, you know that I can't say much about it because it's a consortium of companies taking a Hong Kong company private, a public company private. We announced the plans to acquire Frontage's Pennsylvania bioanalysis and DMPK business. We have announced a purchase price of $470 million with some contingent payments. This is something, this acquisition is squarely in line with the strategy that we discussed, I think at length, at our Investor Day, and we're very excited about it. The bioanalysis is something that the company, we are currently doing. Most of it is in the preclinical space, meaning it supports the in vivo studies we're doing for our clients. We're doing currently $300 million. We said that we expect the five-year target to organically to go to $450 million.
The acquisition will be in addition to that, so we expect additional revenues from that. That was not in the organic target. We expect the acquisition to support us with more capacity and more capabilities, particularly as we support our clients in the preclinical going into the clinical space. What we mean with that, doing the clinical testing, not the clinical trials for our clients. Many of our clients, particularly in complex modalities, would like to stay with one provider. We have a real opportunity here, and we're already working with several of our clients doing that, and that will be an expansion of it.
The bioanalysis, as I said earlier, was an area of growth, even in a downturn, and that comes because complex modalities require more testing, more endpoints, more opportunities for us, and particularly if you're a specialty provider, that is a real growth opportunity. The growth rate in the industry right now is roughly 6%-8%. That would uplift our growth rates a little bit, and we're looking really forward to leveraging this acquisition as well as our organic expansion to accelerate growth rates for Charles River in the future.
I'm going to explore how much you can say now that we're on the mic, but I think you said that the majority of this, 40% of the business is what you are acquiring, and a majority of that is bioanalysis?
What we have said is, we are acquiring, and the math comes out to about a little bit over $100 million of bioanalysis and DMPK. It's mostly bioanalysis.
Bioanalysis. And the majority of that, I think you said in the release, is clinical bioanalysis.
Yes.
All right. Okay. Maybe to finish here, the manufacturing sale of the CDMO cleans up the manufacturing business. That business is now back to upper single-digit organic growth. Margins are very, very good, as you predicted they would be. What portion of that growth is anniversarying, Biologics Testing, kind of easy comp from last year? Essentially, the question is, what upward mobility do the metrics have in that business still?
Yeah. The Manufacturing segment for us is a really interesting segment because of higher growth rates, really good margins, and kind of a lot of reoccurring revenue. This quarter was actually very clean, so there was no impact from a one client-related challenge. The whole growth rate was actually demand and market-driven. Just maybe to finalize, the Manufacturing segment consists out of the Microbial Solutions business, which is a razor and razor blade business where our clients are acquiring equipment and then buying reoccurring reagents. We just had a really good sales of equipment of about nine units. Each of those units translates into roughly $300,000 of annual revenue, just to give you a kind of a way of how we are growing in this business.
The Biologics Testing business is a critical business to anybody manufacturing biologics, and certainly with more onshoring of biologics and more biologics coming through the drug development, we expect this business to continue growing in a really good clip.
Really good is high single digits, double digits?
Really good.
Okay. We'll wrap it there. Thanks, Birgit.
Thank you.
Appreciate your being here.
Thank you.